Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2966316 | Journal of Clinical Lipidology | 2010 | 4 Pages |
Abstract
Options for treatment of severe heterozygous and homozygous familial hypercholesterolemia prior to the statin era were limited by significant side effects and morbidity. The advent of both the statins and technology for the selective removal of LDL via apheresis have revolutionized management but challenges remain.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Linda C. Hemphill,